Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of 2162.HK is 77 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
